Scientific EXPERT Act of 2025

This bill requires the Food and Drug Administration (FDA) to work with the Reagan-Udall Foundation to hold meetings about developing treatments for rare diseases. The meetings must happen at least four times per year, with each meeting focusing on a different rare disease. A steering committee will choose which diseases to discuss based on factors like how many patients have the disease and whether there are existing treatments. The foundation will invite medical experts, drug companies, patient groups, and other organizations to participate, and FDA officials must attend each meeting. After each meeting, the foundation will publish a summary of what was discussed and agreed upon. When the FDA approves a new drug, it must say whether ideas from these meetings influenced its decision.

Your Vote